S&P ASX All Technology

US Dollar vs AUD

Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

Get Started

ASND Ascendis Pharma AS

124.44

0.00 (0.00%)

Pre Market

Last Updated: 22:40:44

Delayed by 15 minutes

Form 144 - Report of proposed sale of securities

="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

Date of Notice

11/19/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

Camilla Harder Hartvig

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Oct 2024 to Nov 2024

Click Here for more Ascendis Pharma AS Charts.

Ascendis Pharma AS (NASDAQ:ASND)
Historical Stock Chart
From Nov 2023 to Nov 2024

Click Here for more Ascendis Pharma AS Charts.

Ascendis Pharma AS News

Form 144 - Report of proposed sale of securities
Wednesday 20 November 2024 (15 hours ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Friday 15 November 2024 (6 days ago) • Edgar (US Regulatory)

Ascendis Pharma Reports Third Quarter 2024 Financial Results
Friday 15 November 2024 (6 days ago) • GlobeNewswire Inc.

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (6 days ago) • Edgar (US Regulatory)

Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
Friday 15 November 2024 (6 days ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 14 November 2024 (7 days ago) • Edgar (US Regulatory)

Ascendis Pharma to Report Third Quarter 2024 Financial Results and Provide Business Update on November 14, 2024
Friday 8 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 4 November 2024 (2 weeks ago) • Edgar (US Regulatory)

Ascendis Pharma and Novo Nordisk Sign Collaboration for Development and Commercialization of TransCon Technology-based Products in Metabolic and Cardiovascular Diseases
Monday 4 November 2024 (2 weeks ago) • GlobeNewswire Inc.

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Thursday 10 October 2024 (1 month ago) • Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]
Monday 30 September 2024 (2 months ago) • Edgar (US Regulatory)

New 3-Year Skeletal Dynamics Data for Adults with Hypoparathyroidism Treated with TransCon™ PTH (Palopegteriparatide) Presented at ASBMR 2024
Monday 30 September 2024 (2 months ago) • GlobeNewswire Inc.

More Ascendis Pharma AS News Articles

Delayed Upgrade Clock

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions